ReCept Pharmacy has been designated by Celgene as one of the specialty pharmacies to distribute Otezla, a new medication for the treatment of psoriatic arthritis.


ReCept Pharmacy, Otezla, apremilast, specialty pharmacies, psoriatic arthritis, specialy pharmacy services


































































































































































































































INSIDE THIS ISSUE
News
Opinion
Other Services
Reprints / E-Prints
Submit News
White Papers

Retail News Breaks Archives

ReCept selected to dispense Otezla

April 14th, 2014

FORT WORTH, Texas – ReCept Pharmacy has been designated by Celgene as one of the specialty pharmacies to distribute Otezla, a new medication for the treatment of psoriatic arthritis.

ReCept said Monday that its has immediate access to dispense Otezla (apremilast) at initial launch. The drug was approved by the Food and Drug Administration on March 21 and became available for dispensing on April 9.

The pharmacy chain noted that Otezla is the first oral therapy approved to treat active psoriatic arthritis. An oral small-molecule, Otezla works by blocking the enzyme phosphodiesterase 4 to reduce swelling in joints and improve physical function in a form of arthritis that afflicts psoriasis sufferers.

Overall, ReCept's network encompasses 16 retail pharmacies in Texas, including five locations providing specialy pharmacy services and a dozen locations offering pharmacy compounding.

Advertisement